Live Breaking News & Updates on Paige Mahaney

Stay updated with breaking news from Paige mahaney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CT pushes for prescription drug price control


CT pushes for prescription drug price control
Julia Bergman
FacebookTwitterEmail
Connecticut and Massachusetts worked together early in the coronavirus pandemic to institute similar restrictions to keep their residents safe, and later to reopen their economies and lift stay-at-home orders.
Now, Govs. Ned Lamont and Charlie Baker are hoping to lead the country in addressing one of the major underlying costs of health care: prescription drug prices.
The governors hosted a joint news conference Tuesday to discuss similar legislation they have proposed in their states, which, they said, would protect consumers and hold drug manufacturers accountable.
Lamont’s two-year budget plan proposes capping annual increases in the cost of prescription drugs. Under the governor’s proposal, yearly hikes would be limited to the rate of inflation plus 2 percent. Drug manufacturers that exceed that amount would be fined, and that money would in turn be used to support subs ....

United States , Jay Gironimi , Karolina Chorvath , Vicki Veltri , Paige Mahaney , Department Of Revenue Services , Connecticut Office Of Health Strategy , Boehringer Ingelheim , Connecticut Program , Revenue Services , Covered Connecticut Program , ஒன்றுபட்டது மாநிலங்களில் , விக்கி வெல்ட்ரி , பைஜ் மஹானே , துறை ஆஃப் வருவாய் சேவைகள் , கனெக்டிகட் அலுவலகம் ஆஃப் ஆரோக்கியம் மூலோபாயம் , போஹெரிங்கர் இஂகல்‌ஹைம் , கனெக்டிகட் ப்ரோக்ர்யாம் , வருவாய் சேவைகள் , மூடப்பட்ட கனெக்டிகட் ப்ரோக்ர்யாம் ,

Opinion: How a CT prescription drug bill would impair research


Opinion: How a CT prescription drug bill would impair research
Paige Mahaney, Ph.D.
FacebookTwitterEmail
Boehringer Ingelheim’s U.S. headquarters in Ridgefield, Connecticut.Contributed photo
I lead Boehringer Ingelheim’s research team in Connecticut, and every day I witness our dedicated scientists striving to discover breakthrough treatments for patients. Our mission compels me to express Boehringer Ingelheim’s opposition to Gov. Ned Lamont’s proposal to set government price controls on prescription drugs (contained in House Bill 6447). The governor’s proposal will not help patients but instead, will hurt the ability of companies like ours to stay focused and invest in research to advance innovative new therapies. ....

United States , Boehringer Ingelheim , Research Development , Governor Lamont , Ned Lamont , Wilton Villager , Paige Mahaney , Global Head Of Biotherapeutics Discovery , Middletown Press , Ridgefield Press , Greenwich Time , News Times , New Haven Register , Connecticut Post , Stamford Advocate , Register Citizen , Wilton Bulletin , Co Vid , Bill 6447 , Research Amp , Head Research Site , ஒன்றுபட்டது மாநிலங்களில் , போஹெரிங்கர் இஂகல்‌ஹைம் , ஆராய்ச்சி வளர்ச்சி , கவர்னர் லாமண்ட் , நெத் லாமண்ட் ,